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Abstract
Background: Angiogenesis is the process of forming new blood vessels from existing ones and requires
degradation of the vascular basement membrane and remodeling of extracellular matrix (ECM) in order to allow
endothelial cells to migrate and invade into the surrounding tissue. Matrix metalloproteinases (MMPs) are
considered to play a central role in the remodeling of basement membranes and ECM. However, MMPs contribute
to vascular remodeling not only by degrading ECM components. Specific MMPs enhance angiogenesis via several
ways; they help pericytes to detach from vessels undergoing angiogenesis, release ECM-bound angiogenic growth
factors, expose cryptic pro-angiogenic integrin binding sites in the ECM, generate promigratory ECM component
fragments, and cleave endothelial cell-cell adhesions. MMPs can also negatively influence the angiogenic process
through generating endogenous angiogenesis inhibitors by proteolytic cleavage. Angiostatin, a proteolytic
fragment of plasminogen, is one of the most potent antagonists of angiogenesis that inhibits migration and
proliferation of endothelial cells. Reports have shown that metalloelastase, pancreas elastase, plasmin reductase,
and plasmin convert plasminogen to angiostatin.
Results: We report here that MMP-19 processes human plasminogen in a characteristic cleavage pattern to
generate three angiostatin-like fragments with a molecular weight of 35, 38, and 42 kDa. These fragments released
by MMP-19 significantly inhibited the proliferation of HMEC cells by 27% (p = 0.01) and reduced formation of
capillary-like structures by 45% (p = 0.05) compared with control cells. As it is known that angiostatin blocks
hepatocyte growth factor (HGF)-induced pro-angiogenic signaling in endothelial cells due to structural similarities
to HGF, we have analyzed if the plasminogen fragments generated by MMP-19 interfere with this pathway. As it
involves the activation of c-met, the receptor of HGF, we could show that MMP-19-dependent processing of
plasminogen decreases the phosphorylation of c-met.
Conclusion: Altogether, MMP-19 exhibits an anti-angiogenic effect on endothelial cells via generation of
angiostatin-like fragments.
Background
Angiogenesis is the process of formation of capillaries
that sprout from existing blood vessels. It plays an
essential role in several physiological processes such as
wound healing, female reproduction, embryonic devel-
opment, organ formation, and tissue regeneration and
remodeling [1]. In pathological processes, the abnormal
growth of new blood vessels can lead to the progression
of many diseases including tumor growth.
Angiostatin is a potent angiogenesis inhibitor specific
for endothelial cells. It is a single chain proteolytic frag-
ment consisting of the first four triple disulfide-linked
kringle domains of plasminogen [2,3]. Functional angios-
tatin-like molecules can be generated from plasmin
reduction and proteolysis [4], plasminogen digestion by
pancreas elastase [5], urokinase-activated plasmin [6],
prostate specific antigen [7], cathepsin D [8], and by sev-
eral matrix metalloproteinases, including MMP-12 [6,9],
matrilysin or MMP-7, MMP-9 [9,10], and MMP-2
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isolated from the inflamed synovium of a rheumatoid
arthritis patient [12], from mammary gland, and liver
[13,14]. Human and murine orthologues of MMP-19
(human: U37791, murine: AF153199) retain the com-
mon domain organization of soluble members of the
MMP family, however, they also contain several distinc-
tive features including a unique cysteine in the catalytic
domain, an altered latency motif, a unique oligogluta-
mate insertion in the hinge region, and a C-terminal tail
[12-17]. MMP-19 is expressed in many tissues at mRNA
level [13,14] although its expression at protein level
appears to be more restricted. Vascular smooth muscle
cells, myoepithelial cells, and basal keratinocytes express
MMP-19 constitutively whereas endothelial cells, epithe-
lial cells of the mammary glands as well as monocytes
and macrophages show differential regulation of this
enzyme [18-23].
MMP-19 was reported to degrade several basement
membrane proteins such as type IV collagen, laminin 5
g2 chain, tenascin C, and nidogen-1 [17,24-26]. This
capacity together with the expression pattern may point
to a role of MMP-19 in vascular remodeling and angio-
genesis. In the present study, we report that recombi-
nant MMP-19 specifically generates angiostatin-like
fragments from plasminogen, which inhibit proliferation
and capillary-growth of endothelial cells.
Results
GST-MMP-19 processes Glu-type plasminogen to
angiostatin-like fragments
To assess if plasminogen is a substrate of MMP-19, we
used two types of the protein, Glu- and Lys-type plasmi-
nogen. Whereas the Glu-variant is the native form of
the protein, the Lys-variant is generated by cleavage of
the peptide bond between Lys77 and Lys78 by plasmin.
In contrast to the Glu-type plasminogen, we observed
self-degradation of the Lys-type form, even in the pre-
sence of the serine protease inhibitor aprotinin. Thus,
we decided to continue the experiments with the Glu-
type variant, which does not have any plasmin activity
and nearly no self-degradation. As controls, we used
samples with MMP inhibitor (MMP-9/MMP-13 inhibi-
tor II) or the inactive MMP-19 mutant (E213A) instead
of the wild-type fusion protein. The MMP-19 fusion
protein was generated and purified as described in
“Methods”. The expected size of the purified fusion pro-
tein was 85 kDa as detected by Coomassie staining and
immunoblotting using anti-MMP-19 antibody (Figure 1,
arrowhead). The strong protein band of approximately
4 0k D aa p p e a r i n gi nt h eC o o m a s s i es t a i n e dS D S - P A G E
is a peptide composed of the N-terminal GST-tag and
the propeptide domain of MMP-19, which is generated
during purification due to autocatalytic activity of
MMP-19.
We also used recombinant murine MMP-9 in an
initial experiment as it was published that MMP-9 gen-
erates angiostatin like fragments [10]. The same experi-
mental conditions were applied to both MMPs to be
able to compare their efficiency of both MMPs. The
processing of plasminogen by MMP-9 was not as effi-
c i e n ta st h eo n eo fM M P - 1 9 ,t h u s ,i tw a sn o ti n c l u d e d
in the following experiments (Figure 2A).
Processing of human Glu-type plasminogen by MMP-19
for 96 h generates several fragments with an apparent mole-
cular weight of 35 (kringle 1-3), 38 (kringle 1-4), and 42
kDa (Figure 2A), some of them correspond to the angiosta-
tin-like fragment (38 kDa). The protein band about 92 kDa
represents the full-length Glu-type plasminogen. As the
angiostatin-like fragments consist of the N-terminal part of
plasminogen the bands below 66 kDa are the corresponding
C-terminal parts of the cleaved protein. Comparing the
time course of this reaction, an increase of the putative
angiostatin-like fragments over time was obvious (Figure
2B). Fragments that occurred and disappeared during the
incubation are intermediate products that are further pro-
cessed to the final pattern of fragments (Figure 2B).
Plasminogen processed by GST-MMP-19 inhibits
proliferation of microvascular endothelial cells
To investigate anti-angiogenic properties of generated
plasminogen fragments, we first analyzed their effect on
proliferation of HMEC-1 endothelial cells using the Ala-
mar Blue proliferation assay (Biosource). Cell
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Figure 1 Purification and detection of recombinant GST-MMP-
19 proteins. (A) 5 μg purified active MMP-19 protein (WT) and the
mutant inactive form of MMP-19 harbouring the exchange of E213
to A (EA) were subjected to SDS-PAGE and stained with silver
staining. (B) Purified MMP-19 WT and EA protein (5 μg) were
detected by Western blotting using rabbit polyclonal antibodies
(Dianova, dilution 1:3000). Arrowheads indicate MMP-19 at 85 kDa.
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in the presence of the processed plasminogen and was
reduced about 27% compared to full-length plasminogen
after 30 h (Figure 3B). This proliferation decrease
appears to be due to the presence of active angiostatin-
like fragments in the digested plasminogen mixture.
Recombinant MMP-19 (2 μg/well) alone does not show
any inhibition of the proliferation.
Capillary-like formation is inhibited by fragments
generated by MMP-19
To assess the effect of plasminogen fragments generated
by MMP-19 on endothelial cell differentiation, in vitro
angiogenesis assays were performed. HMEC-1 cells were
placed on Matrigel in EGM-MV medium containing
recombinant MMP-19 (1 μg/well), plasminogen (1.25
μg/well), or cleavage products of plasminogen. The cells
were examined after 24 h of incubation regarding the
induction of formation of tube-like structures (Figure
3C). The tube formation of the cells treated with the
processed plasminogen mixture was remarkably reduced
in comparison to the control. The amount of capillary-
like structures was about 47% less in the treated than in
control wells (set to 100%; Figure 3D).
Plasminogen processed by GST-MMP-19 decreases the
phosphorylation of c-Met and Akt/PKB
Because angiostatin blocks HGF-induced angiogenesis
by inhibition of phosphorylation of its cell surface
receptor c-Met, we analyzed whether the angiostatin-
like fragments generated by MMP-19 mediated the
described effects [27,28]. As demonstrated by Western
blot analysis, phosphorylation of c-Met in HMEC-1 cells
was inhibited by 27% after treatment with processed
plasminogen compared to plasminogen (Figure 4A and
4B). We further analyzed phosphorylation of Akt/PKB
after treatment with the angiostatin-like fragments.
Apart from c-Met, Akt signaling is also essential in
angiogenesis as it affects the cell cycle and therefore
proliferation. We observed a decrease of 45% of the
phosphorylated form of Akt kinase after treatment with
processed plasminogen compared to plasminogen (Fig-
ure 4C and 4D).
Discussion
Plasminogen, a single-chain glycoprotein of 92 kDa con-
sisting of an N-terminal peptide, five kringle domains,
and a serine protease domain [29], plays a crucial role in
tumor metastasis and angiogenesis where localized pro-
teolysis is required. Under certain conditions, plasmino-
gen undergoes proteolysis to form kringle-containing A-
chain fragments, collectively called angiostatins [2,30,31],
which are novel and potent inhibitors of endothelial cell
proliferation and tumor angiogenesis [9]. Typically,
angiostatin consists of the first four kringle domains (K1-
4). Plasminogen is cleaved by several proteases, among
them members of matrix metalloproteinase family, that
are derived from tumor cells or infiltrating macrophages
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Figure 2 Processing of human plasminogen by GST-MMP-19.( A )2 0μg Glu-type plasminogen was either left undigested (lane 1) or was
digested for 60 h by 5 μg MMP-9 (lane 2) which was activated before the digest with trypsin at 37°C for 20 min or 15 μg GST-MMP-19 (lane 3)
at 37°C for 96 h. Digests were subjected to SDS-PAGE followed by Coomassie staining. Angiostatin-like fragments generated by MMP-19 are
indicated by arrowheads. (B) Time course of human plasminogen processing by GST-MMP-19. 10 μg Plasminogen was digested by 8 μg GST-
MMP-19 at 37°C for 96 h. Samples were analyzed at 0, 24, 48, 72, and 96 h on SDS-PAGE followed by silver staining. The mixture of digested
plasminogen fragments was used without further purification in the tube-like formation assay.
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Page 3 of 8[8,32]. These kringle domains and their relatives inhibit
the proliferation of vascular endothelial cells, a funda-
mental process in angiogenesis [31].
As MMP-19 was reported to be expressed by endothe-
lial cells as well as cells that surround endothelium and
capillaries, it could be expected that its activity likely
impacts vascular processes including angiogenesis. Our
experiments show that MMP-19 has angiostatin-con-
verting enzyme activity and generates angiostatin-like
fragments similar to MMP-3, -7, -9, and -12 [9-11]. The
cleavage site is located between kringle 5 and the pro-
tease domain to generate angiostatin molecules consist-
ing of all five kringle domains of plasminogen. As all
reported angiostatin species exhibit the biological activ-
ities of angiostatin isolated from plasma (e.g. inhibition
of endothelial proliferation, angiogenesis, and tumor
growth and metastasis), the angiostatin-like fragments
generated by MMP-19 should also have such biological
activities.
Angiogenic growth factors and inflammatory cytokines
can induce a number of pericellular acting proteases,
including MT1-MMP, MMP-2, MMP-9, and u-PA. This
is generally seen as a part of the repertoire of cellular
activities that are switched on when the pro-angiogenic
growth factors overrule the angiogenesis-inhibiting fac-
tors. However, this unidirectional view on the relation
between angiogenic growth factors and proteases has
e v o l v e di n t ot h ei n s i g h tt h a tp r o t e a s e st h e m s e l v e sa l s o
contribute to fine-tuning of the activities of various
growth factors that control the onset and progression of
angiogenesis [33-35]. Different members of the MMP
family may generate angiostatin-like fragments with dif-
ferent efficiency and with different composition. The
contribution of MMP-19 and other MMPs to angiosta-
tin generation in vivo will depend on their expression
pattern, the rate of their activity, and also inactivation
by endogenous inhibitors. This mechanism may be
further complicated by interactions between different
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Figure 3 Effect of plasminogen processing on cell proliferation and angiogenesis. (A) Proliferation of microvascular endothelial cells HMEC-
1 is inhibited by GST-MMP-19 processed plasminogen. Plates were coated as follows: black diamond, plasminogen; black circle, aprotinin; black
square, processed plasminogen; black triangle, processed plasminogen with MMP inhibitor; inverted black triangle, MMP inhibitor; + (plus
symbol), GST-MMP-19 wild-type; cross, GST-MMP-19 inactive mutant. Proliferation was measured over 30 h with 2500 HMEC-1 cells per well and
using the Alamar Blue assay. Standard deviation was calculated from triplicates. (B) Proliferation in response to processed plasminogen compared
to non-processed plasminogen at assay endpoint (30 h); * p = 0.01 (C) In vitro angiogenesis assay. Processed plasminogen inhibits capillary-like
structure formation of HMEC-1 cells (D) The length of tubuli-like structures was measured in at least three wells per experiment. The mean ± SD
of the tubuli length is given as the percentage of the control. * p = 0.05.
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Page 4 of 8MMPs as well as by multiple proteolytic activities
towards extracellular matrix proteins in basement mem-
brane or vascular bed. Thus, MMP-19 could further
increase its anti-angiogenic effect by damage of base-
ment membrane scaffold that supports differentiation
processes of endothelial cells. MMP-19 could achieve
this by cleavage of at least three important basement
membrane components: tenascin C, g2chain of laminin5,
and nidogen-1 [24-26]. In our previous study we could
show that high concentrations of MMP-19 might have
negative influence on endothelial cell growth as MMP-
19-dependent processing of nidogen-1 led to inhibition
of tube-like formation in vitro [24]. As higher concen-
trations of MMP-19 could influence or interfere with
effects of processed plasminogen we tested the remain-
ing MMP-19 fusion proteins in the processed plasmino-
gen mixture on endothelial cells as well. However,
MMP-19 under these experimental conditions did not
exhibit any effect on the cells.
Moreover, current data show that MMP-19 exhibit
also critical antitumor activity as secreted active MMP-
19, but not the inactive mutant, induces reduction of
tube-forming ability in endothelial cells with decreased
vascular endothelial growth factor (VEGF). Thus, MMP-
19 seems to be responsible, at least partly, for bioavail-
ability of MMP-2 and VEGF that promote angiogenesis
[36]. In contrast, the MMP-19-deficient mice showed
decreased tumor angiogenesis and invasion [37] point-
ing, thus, to a potential dual role of MMP-19. The pro-
angiogenic role of MMP-19 could be associated with its
expression in microvascular endothelial cells or smooth
muscle cells [19], and in the controlled release of pro-
angiogenic factors such as VEGF and MMP-2; the anti-
angiogenic effect of MMP-19 might originate from
uncontrolled overproduction of this MMP from various
surrounding cellular sources, which can disrupt the
necessary ECM scaffold or, as here reported, produce
angiostatin-like fragments.
As MMP-19 generates angiostatin-like fragments that
subsequently inhibit endothelial cell proliferation and
tube-like formation, we asked, which pathways are
involved in this inhibition. c-Met is the HGF receptor
that controls cellular mobility due to tyrosine-kinase
activity. HGF binding to its receptor induces the
%
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Figure 4 Angiostatin inhibits phosphorylation of c-Met and Akt/PKB in HMEC-1 cells. HMEC-1 cells were incubated at 37°C and 5% CO2
for 40 h. For the treatment with plaminogen mixture, 2 μg/well recombinant MMP-19, or aprotinin 1 ug/ml were used. Cell lysates were
prepared and analyzed by 12.5% SDS-PAGE followed by immunoblotting for phospho-cMet (A) and phospho-Akt/PKB (B). Blots were then
stripped and re-probed for b-actin as a loading control. Quantification of phospho-cMet and phospho-Akt/PKB protein was performed by
densiometric analysis using the Aida Image Analyser and normalized for the signal intensity of the beta-actin band. Densitometric analysis;
intensity of phospho-c-Met (B) and phospho-Akt/PKB (D) bands was normalized to the corresponding signal intensity of b-actin bands and the
buffer control was set as 100%. Sodium phosphate, used as buffer for the above experiments, was used as a control. One of two independent
experiments is shown.
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domain that initiates the intracellular signaling. Angios-
tatin has structural similarities to HGF that promotes
angiogenesis, induces proliferation, migration, and also
influences cell survival via its cell surface receptor, c-
Met. Upon HGF stimulation, c-Met induces several bio-
logical responses that collectively give rise to a program
known as invasive growth. It is thought that angiostatin
inhibits HGF-induced phosphorylation of c-Met, Akt,
and ERK1/2 via binding to soluble c-Met. Angiostatin
and c-Met form a stable complex and affect signaling
events induced by HGF but not by VEGF or bFGF [27].
The inhibition of Akt phosphorylation by angiostatin
is not solely a marker for the inhibition of HGF binding
to c-met; instead, a reduction in phospho-Akt could
directly contribute to the disruption of angiogenesis.
Akt is a serine/threonine kinase that is rapidly activated
as a downstream effector of phosphatidylinositol 3 (PI3)
kinase in response to a variety of cytokines and growth
factors, including HGF [38]. In this work we could show
that MMP-19-processed plasminogen inhibits the HGF-
induced phosphorylation of c-Met and Akt/PKB and
that plasminogen fragments generated by MMP-19
impact proliferation and tube-like formation of endothe-
lial cells.
Conclusion
We report here that MMP-19 processes human plasmi-
nogen and generates angiostatin-like fragments that
inhibit proliferation microvascular endothelial cells,
decreases the phosphorylation of c-met, and reduce for-
mation of capillary-like structures. Thus, MMP-19 exhi-
bits an anti-angiogenic effect on endothelial cells via
generation of angiostatin-like fragments.
Methods
Expression and purification of human MMP-19 GST-fusion
protein (GST-MMP-19)
MMP-19 was produced as a fusion protein with glu-
tathione-S-transferase (GST) in the BLR (DE3) strain of
E. coli (Novagen, Darmstadt, Germany) using the
expression vector pGEX-2T. The recombinant protein
starts N-terminally with the GST fused in frame to Phe,
the first amino acid of the propeptide domain, and ends
with Arg, the first amino acid of the 36 amino acid-long
C-terminal tail. The expression of MMP-19 was induced
by 0.6 mM Isopropyl-1-thio-D-galactopyranoside
(IPTG). MMP-19 was produced as a fusion protein of
glutathion-S-transferase (GST) and MMP-19 as
described [23,25]. Purification was done according to
Rohman and Harrison-Lavoie [39] with slight modifica-
tions. In brief, the pelleted bacteria were resuspended in
20 ml buffer A (sonication buffer) (100 mM Triethano-
lamine-HCl (TEA-HCl), 150 mM NaCl, 1% Triton X-
100, pH 7.4) and disrupted in the presence of Comple-
te™proteinase inhibitor (Roche, Mannheim, Germany)
by sonification. The sonicate was pelleted and the super-
natant transferred into 4 ml of buffer B (100 mM TEA-
HCl, 200 mM MgCl2, 500 mM KCl, 100 mM ATP, pH
7.4) and incubated for 30 min at room temperature.
This step was followed by an incubation for 45 min
with 0.5 ml 50% slurry of Glutathione Sepharose 4B (GE
Healthcare, Freiburg, Germany). The gel was washed
three times with 10 ml buffer C (100 mM TEA-HCl,
150 mM NaCl, 20 mM MgCl2,5 0m MK C l ,1 %T r i t o n ,
10 mM ATP, protease inhibitors, pH 7.4). In the last
w a s h i n gs t e pb u f f e rDw a su s e d( 1 0 0m MT E A - H C l ,
150 mM NaCl, 20 mM MgCl2,5 0m MK C l ,5m M
ATP, pH 7.4). For elution of the bound fusion protein
we used 50 mM Tris-HCl with 10 mM reduced glu-
tathione, pH 8.0 which is prepared freshly prior use. We
performed 5 elutions and analyzed them by SDS-PAGE.
The fractions were pooled and dialysed over night at 4°
C against 2 l TNC buffer (50 mM Tris-HCl, 150 mM
NaCl, 5 mM MgCl2,5m MC a C l 2,p H7 . 4 )u s i n ga
Slide-a-lyser cassette (PIERCE, Ulm, Germany) to get
rid of the reduced glutathione. The concentration was
determined using BCA kit (PIERCE, Ulm, Germany).
Immunoblotting for MMP-19 was performed using a
rabbit polyclonal antibody (Dianova, dilution 1:3000)
against the hinge region of MMP-19. This antibody
detected the zymogen, the active protein as well as wild-
type (WT) and inactive mutant (EA).
The murine proMMP-9 protein as a control was
expressed in Cos7 cells. The protein was purified by affi-
nity chromatography binding to a gelatine sepharose
column (GE Healthcare, Freiburg, Germany). Before
using recombinant MMP-9 in the cleavage assay it has
to be activated with trypsin (10 μg / m l )a t3 7 ° Cf o r2 0
min. The reaction was stopped by adding trypsin inhibi-
tor (1 mg/ml).
Preparation of proteolytic fragments of plasminogen and
analysis
The processing of 10 μg plasminogen (human Glu-type
plasminogen, Calbiochem or Lys-type plasminogen,
Chromogenix) was done in TNC buffer + 10 μM ZnCl2,
pH 7.4 with 50 μl GST-MMP-19 (8 μg) at 37°C for 96
h; samples were taken every 24 h. To determine the spe-
cificity we used the following controls: One control was
without any enzyme to observe the self-processing. Sec-
ond control was the use of GST-MMP-19 inactive
mutant (E213A) instead of active protein. Third control
contained an MMP-19 inhibitor (10 nM; MMP-9/MMP-
13 inhibitor II, Calbiochem), which was chosen because
of the strong inhibition of recombinant human MMP-19
(data not shown). To avoid the activation and the auto-
catalytic activity of the zymogene plasminogen to its
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protease inhibitor Aprotinin (1 μg/ml; Sigma, Germany).
Also a control without Aprotinin was analyzed. To com-
pare the efficiency of the cleavage to other MMPs 10 μg
plasminogen (human Glu-type plasminogen, Calbio-
chem) was incubated with 5 μg recombinant MMP-9
using the same experimental conditions. proMMP-9 was
activated prior to trypsin treatment at 37°C for 20 min.
The mixture of digested plasminogen fragments was
used without further purification in the tube-like forma-
tion assay.
Cell culture
Human microvascular endothelial cells (HMECs), kindly
provided by Prof. Marmé (Freiburg, Germany), were cul-
tured in Endothelial Cell Growth Medium MV with Sup-
plement Mix (EGM-MV) (Promocell, Heidelberg,
Germany) in a humidified atmosphere of 5% CO2 at 37°C.
Endothelial cell proliferation assay
A 96-well flat bottom plate was coated with GST-MMP-
19 processed plasminogen or the following controls:
unprocessed plasminogen (2.5 μg/well), GST-MMP-19
WT or EA (2.0 μg/well), GST-MMP-19 with inhibitor,
aprotinin, or TNC buffer. An uncoated plate served as
additional control. HMECs were then added (2500 cells/
well) and the plate incubated at 37°C with 5% CO2.T o
evaluate the effect of the processed Glu-type plasmino-
gen on cell proliferation, we used the Alamar Blue col-
orimetric assay (Biosource, Solingen, Germany)
according to the manufacturer’s instructions.
Immunoblotting
HMEC-1 cells, were grown for 40 h in EGM-MV (Pro-
mocell) supplemented with reaction buffer (sodium
phosphate) alone, with aprotinin (1 μg/ml), with MMP-
19 (2 μg/well), or with processed and unprocessed plas-
minogen as described above. Cell lysates were prepared
as described previously and 40 μg protein per sample
was applied to SDS-PAGE; anti-phosphorylated c-Met
(Biosource, dilution 1:500 in TBS + 1% BSA) or anti-
phosphorylated Akt/PKB (Biosource, dilution 1:500 in
TBS + 1% BSA) were used for detection. Bound anti-
body was detected using peroxidase-conjugated anti-rab-
bit antibody (PIERCE, USA) and the ECL plus Western
Blotting Detection System (GE Healthcare, UK). Signals
were recorded with a Luminescent Image Analyzer
(LAS-3000, Fujifilm Life Science, USA) and analyzed
with AIDA image analysis software (Raytest, Strauben-
hardt, Germany). Densitometric scans of the signal
intensity of phospho-c-Met and phosphor-Akt/PKB
bands are normalized for the corresponding signal
intensity of b-actin bands; the buffer control was set as
100%.
Tube-like formation assay in vitro
To evaluate the angiogenic effects of the plasminogen
fragments in vitro, a tube-like formation assay was
adapted from Kubota et al. [40] and Donovan et al [41].
Shortly, Matrigel (BD Bioscience, Heidelberg, Germany)
was coated according to the manufacturer’sp r o t o c o l .
The inner well of angiogenesis plates (μ-Slide Angiogen-
esis, ibidi, Martinsried, Germany), were filled with 10 μl
Matrigel. The plate was incubated for 37°C to allow the
Matrigel to gel and 5000 HMEC-1 cells per well were
seeded onto the matrix. Images were captured using a
digital camera and Olympus IX 51 microscope. Capil-
lary-like formation, i.e. tubuli length, was evaluated after
24 h of incubation at 37°C. Two independent experi-
ments were conducted and at least 3 wells evaluated per
experiment. The total length of tubuli was measured in
pixels using the image analysis software imageJ (NIH,
US). The tubuli length is given as mean percentage of
the control (± SD). To study the effect of the processed
plasminogen the fragments were added to HMEC-1
cells. The same amount of non-processed plasminogen
(1.25 μg/well) and recombinant MMP-19 (1 μg/well)
was used as controls.
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human microvascular endothelial cells; HGF: hepatocyte growth factor; IPTG:
isopropyl-1-thio-β-D-galactopyranoside; VEGF: vascular endothelial growth
factor; bFGF: basic fibroblast growth factor.
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